San Francisco Partner Judith Waltz was quoted in an article titled “Sunshine Act Compliance Stymies Healthcare Firms” in the July 2013 issue of Compliance Week. The article discusses the impact the Sunshine Act will have on drug companies and medical equipment companies. Ms. Waltz was quoted saying, “This may relate to concerns about how their participation will be viewed by patients, or to the increasing prevalence of institutional policies that limit or even preclude involvement in any activity that might be viewed as a conflict of interest for clinical decision making. [If this trend continues,] it could result in some significant constrictions on future research and clinical discussion of existing drugs.”
People
Related News
14 February 2025
In the News
Brian Wheeler Joins Podcast to Discuss Legal Journey
Foley & Lardner LLP partner Brian Wheeler joined the Hsu Untied podcast to discuss his legal career.
14 February 2025
In the News
Pavan Agarwal Featured in Leadership Q&A – 'Reflecting our firm’s core values drives me to do my best'
Foley & Lardner LLP partner Pavan Agarwal is featured by Law.com for his career journey, legal practice, and leadership in the article, “How I Made Practice Group Chair: ‘Keep Listening and Keep Learning,’ Says Pavan Agarwal of Foley & Lardner.”
14 February 2025
In the News
Judith Waltz on Trump Administration Deregulation Order, Impact on CMS
Foley & Lardner LLP partner Judith Waltz commented on the Trump administration's executive order requiring federal agencies cut ten regulations for each newly created one in the Modern Healthcare article, "CMS may evade Trump's sweeping deregulation order."